Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS: Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients. RESULTS: Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA1c versus empagliflozin at week 26 (treatment policy –1.3% vs. –0.9% [–14 vs. –9 mmol/mol], estimated treatment difference [ETD] –0.4% [95% CI –0.6, –0.3] [–5 mmol/mol (–6, –3)]; P < 0.0001). The treatment difference in HbA1c significantly favored oral semaglutide at week 26 for the trial product estimand (–1.4% vs. –0.9% [–15 vs. –9 mmol/mol], ETD –0.5% [95% CI –0.7, –0.4] [–6 mmol/mol (–7, –5)]; P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product −4.7 vs. −3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide. CONCLUSIONS: Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in the randomised, open-label, multinational 52-week PIONEER 2 trial, oral semaglutide 14 mg resulted in a significantly greater reduction in CRP compared with empagliflozin 25 mg.23”
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [20]
In the citing paper
“In PIONEER 2, oral semaglutide reduced CRP by 30%, whereas empagliflozin had no effect despite similar approximately 4% weight loss (24).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [24]
In the citing paper
“In the PIONEER program, four thyroid malignancies occurred in semaglutide-treated patients, versus one in the comparator group”
From Safety of Semaglutide (2021) · cites this paper as [15]
In the citing paper
“The ‘PIONEER’ series of trials [21–30] demonstrated that oral semaglutide has a positive impact on average HbA1c levels and weight reduction compared with several other drug classes (SGLT-2 inhibitor, DPP-4 inhibitor, another GLP-1RA, insulin and placebo).”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [22]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Self-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†An episode that is severe, according to theADAclassification (requires assistanceof anotherperson to actively administer carbohydrate, glucagon, or other corrective action) (29).”
BackgroundUser’s manual for the SF-12v2 health survey
Ware, J., Kosinski, M., Bowker, D., Gandek, B., Ware, J. E., & Turner‐Bowker, D. M. (2002) · Cited by 1,085
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Self-citationSorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Cited by
Items 401–482 of 482
La oportunidad que supone disponer de un arGLP-1 oral
Orozco‐Beltrán, D. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.manejointegral.art4
Pleiotropic Benefits with Glucagon-like Peptide-1 Receptor Agonists: A Clinical Review
PATANGE, S. A., Singh, S. K., Bhattacharyya, S., Jagadeesha, A., Bhartia, M., Aneja, P., Hendral, A., & Chaudhuri, S. R. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_19_23
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
GLP-1 RECEPTORIŲ AGONISTŲ REIKŠMĖ 2 TIPO CUKRINIU DIABETU SERGANČIŲ PACIENČIŲ SVORIO MAŽINIMUI
Viliušytė, M., Maleckas, A., & Malinauskas, M. (2024) · Health Sciences · doi:10.35988/sm-hs.2024.021
Rico-Fontalvo, J. E., Daza-Arnedo, R., Vázquez, L. C., Yánez, T. R., Raad-Sarabia, M., Toapanta, N., Rafael-Vicente, P., Montejo-Hernández, J. D., & Soler, M. J. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000021
Rico-Fontalvo, J. E., Daza-Arnedo, R., Vázquez, L. C., Yánez, T. R., Raad-Sarabia, M., Toapanta, N., Rafael-Vicente, P., Montejo-Hernández, J. D., & Soler, M. J. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.23000052
Review of Efficacy and Safety of Semaglutide in the Management of Obesity
Han, S., & Park, T. E. (2024) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2024.34.1.1
Alarcón‐Romero, L. D. C., Zubillaga‐Guerrero, M. I., William, C. I. M., Illades‐Aguiar, B., García, A. M. E., Rivera, M. J. M., Barrera, J. A. P., Gómez‐Gómez, Y., & Hernández, M. V. (2024) · doi:10.22533/at.ed.8022401044
A CONEXÃO CURIOSA ENTRE DIABETES MELLITUS E A DOENÇA DE PARKINSON
Maciel, L. M., dos Santos, A. V. F., da Silva, C. V. B. G., dos Santos, G. L. G., Galdino, E. D. S., de Moraes, J. G. F., Miranda, M. A., Silva, M. A. P. D. C. C., Barbosa, J. O. L., & de Lira, A. C. L. (2024) · doi:10.22533/at.ed.8022401047
FATORES QUE INFLUENCIAM NA PREMATURIDADE
Carneiro, C. R. D. N., Reis, C. C. C., Dias, R. A., Sales, E. Q., Ferreira, T. P. A., Silva, P. S. L. E., Costa, P. N., Soares, J. B., Reis, M. C. P., Fernandes, L., et al. (2024) · doi:10.22533/at.ed.8022401043
de Freitas, S. S., Alves, J. D. L., da Silva, W. L. S., Paulino, B. D. S., Prado, N. S., de Arruda, M. A., Amancio, S. R. F., de Barros, C. F. E., Bezerra, A. M. F. D. A., de Souza, F. R., et al. (2024) · doi:10.22533/at.ed.8022401046
IMUNOLÓGICOS ENVOLVIDOS NA PATOGÊNESE DA DOENÇA PERIODONTAL
Freire, J. M. D. O., Sousa, L. M. V. L., Rodrigues, Í. A., de Sousa, B. S., de Menezes, R. L. R., Nascimento, A. L. S., de Oliveira, M. M., & da Costa, I. B. (2024) · doi:10.22533/at.ed.8022401042
CUIDADOS PALIATIVOS NEONATAIS PARA A FAMÍLIA
Silva, F. A., Chady, C. S., & Dias, R. A. (2024) · doi:10.22533/at.ed.8022401045
USO DE PSICOTRÓPICOS EN CULTURAS ANCESTRALES: UN VIAJE A TRAVÉS DEL TIEMPO Y LAS TRADICIONES
de Aparicio, C. X. P., Guerrero, D. A. H., & Pazmiño, P. V. L. (2024) · doi:10.22533/at.ed.8022401041
Singh, A. K., & Chawla, R. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01337-1
Sinha, B., Ghosal, S., Gangopadhyay, K. K., Sanyal, D., Ray, S., & Mazumdar, A. (2024) · Journal of Diabetes and Treatment · doi:10.29011/2574-7568.010135
Semaglutide in the Treatment of Diabetes and Associated Obesity
Makuch, R., Chrościcka, A., Gała, K., Czajka, A., Lenard, P., Kucharski, A., Michalska, S., Pilarski, K., Dewicka, M., & Wawrzyniak, A. M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.73.51699
The efficacy of oral semaglutide in weight loss and glycemic control
Lopes, C. A., Lima, L. D. S., Eccard, J. V. A. A., & Gama, L. L. (2024) · International Journal of Health Science · doi:10.22533/at.ed.1594552414069
Hussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
Self-citationSind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Aristizabal-Colorado, D., Trujillo, D. A. V., del Castillo, S. S. F., Martinez, W. A. R., Badiel, M., & Abreu-Lomba, A. (2025) · Cureus · doi:10.7759/cureus.83416
(2025) · Texila international journal of academic research · doi:10.21522/tijar.2014.12.02.art012
Okamoto, A., Yokokawa, H., Morimoto, A., Goto, K., Fukuda, H., Hisaoka, T., & Naito, T. (2025) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2025.152007
Bruglia, M., Cardini, F., Luzio, R. D., Fiorini, S., Guberti, A., Haddoub, S., Preiato, V. L., Luberto, A., Lugli, F., Maiello, M., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01762-3
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Ormanac, K., Božek, T., Žuljević, K., Grbavac, J., Petrinović, M., Majanović, S. K., Canecki-Varžić, S., Berković, M. C., & Bilić-Čurčić, I. (2025) · Diabetology · doi:10.3390/diabetology6110127
Garma, J. L., Mouce, C. G., Novo, N. R., Trastoy, O. D., Nieto, A. S., Castro, P. P., Ortega, C. D., Rodríguez, E. F., Carballeira, R. P., Osorio, I. P., et al. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501713
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031555
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031567
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031546
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031564
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031558
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031549
Self-citationTsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574907
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574919
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031561
Self-citationTsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574922
Freitas, J., Machado, S. N., Vieira, B., Monteiro, S., Faria, S., Costa, T., & Mota, C. (2024) · Scientific Repository of Open Access of Portugal (RCAAP)
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031552
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031570
Self-citationTsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574910
Mosenzon, O., Capehorn, M. S., Remigis, A. D., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Figshare · doi:10.6084/m9.figshare.20882123
Self-citationTsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574913
Dionne, V. (2024) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/27748 · Cited by 1
Aktuelle Therapiekonzepte und Entwicklungen in der Diabetes mellitus Typ 2-Therapie
Honskamp, A. K. (2021) · Unipub UB Graz (Universität Graz)
Betere glycemiecontrole met semaglutide dan met canagliflozine wanneer toegevoegd aan metformine?
Goderis, G. (2020) · Lirias
Omori, Y., Usui, R., Yamazaki, Y., Kuwata, H., Hamamoto, Y., Yamada, Y., & Seino, Y. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70240
Labate, A. M., Moretti, L., & Villari, P. (2026) · Endocrines · doi:10.3390/endocrines7010008
González-Gálvez, G., Garnica-Cuéllar, J. C., Colín‐García, M. Á., Ferreira‐Hermosillo, A., Jimenez-Ramos, S. A., Contreras-Sandoval, A. Y., Cruz-Puente, P., & Duarte-Vega, M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70219
Zaccardi, F., Aroda, V. R., Arslan, E. G., Bardtrum, L., Goldney, J., Ising, E., Priyadarshini, P., Slater, T., & Davies, M. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70770
Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance
Zinzi, A., Gaio, M., Ruggiero, R., Mascolo, A., Riemma, M. A., Cipriani, M., Laino, L. V., Berrino, L., Rossi, F., & Capuano, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1805842 · Cited by 1
Handelsman, Y., Cheng, A. Y. Y., Fadini, G. P., Kushner, P. R., Bonnet, F., Fioretto, P., KADOWAKI, T., Kanumilli, N., Cos, X., Frese, T., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03618-z
What Observational Research Contributes and What It Requires
Curtis, L. H., & Dhruva, S. S. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.079
Real World Evidences and Identifying the Gaps and Future Prospects with Incretin Therapy in India
Khare, J., Ghosh, M. A., Kaduskar, A., Babu, V., Mohan, B. J., AHMED, D. R., Poul, S., Singh, M. M., Gupta, R., Singh, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_28_26
Badgandi, M., Srinath, A., Mandora, V., Kandar, D. K., Shukla, P., PUNATAR, D. H., Jain, V., Kumar, S., Girish, P., Budhwar, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_20_26
Cardio-Kidney-Metabolic Syndrome and Role of Oral Semaglutide
Roy, N., Nallaperumal, S., Mondal, S., Mathur, R., Prakash, A. S., Chakraborty, S., Vedire, A., Ankathi, S. K., Bande, A. R., & Boppana, R. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_24_26
Meng, X., Duanmu, Y., Yu, X., Liu, L., Yuhui, C., Chen, Z., 纪桂元, Zhang, D., Yang, X. H., Liu, X., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1786243
Targeting inflammatory pathways in T2DM: Therapeutic interventions
Ali, S., & Jamous, Y. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33590-7.00003-4
The systems medicine view of semaglutide: from clinical trials to molecular mechanisms
Vitorino, R. M. P. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2695172
The Risk of Retinal Vascular Events in Patients Using Semaglutide: A Scoping Review
Goudira, S. C., Højlund, K., & Grauslund, J. (2026) · Ophthalmologica · doi:10.1159/000553235
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
As, A., Балыкова, Л. А., Zaslavskaya, K. Y., Shohin, I. E., Геннадьевна, Б. Т., Zorina, L. A., Shcherbakova, V. S., Куркин, Д. В., Koryanova, K. N., Mishchenko, E. S., et al. (2026) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2026-14-4-387-409
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Wang, L., Jiang, F., Yuan, S., Sun, J., Zhao, J., Zhou, S., Liang, J., Li, H., Song, P., Wang, S., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156711
Dizdarević-Bostandžić, A., Hadzigrahic, E., & Nišić, A. (2026) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2026-001616
Aladhab, R. A. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20262782
Lin, C.-H., Hung, P., Chung, M., Wu, L.-Y., & Chung, C. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100645 · Cited by 2
Immunosenescence in Cardiovascular-Kidney-Metabolic Syndrome: A Unifying Mechanistic Framework
Sano, M. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0060
Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities
Vahora, S., Shah, V., & Patel, B. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04185-2 · Cited by 2
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
Chirapongsathorn, S., & Tacke, F. (2026) · Digestion · doi:10.1159/dig/acmag014
ACHIEVE-2: Orforglipron vs. Dapagliflozin bei unzureichend kontrolliertem Typ-2-Diabetes
Weiner, J. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01510-6
Guo, L., Yu, D., XU, Y., Tang, G., Peng, L., Meng, C., Zhao, M., Hu, W., Huang, D., Zeng, C., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04713-y · Cited by 1
Сергеевич, А. А., Александровна, Б. Л., Яковлевна, З. К., Евгеньевич, Ш. И., Геннадьевна, Б. Т., Анатольевна, З. Л., Сергеевна, Щ. В., Владимирович, К. Д., Koryanova, K. N., Сергеевна, М. Е., et al. (2026) · Pharmacy & Pharmacology
Stüdemann, S., Gollasch, M., & Engeli, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786211
Liu, F., Xu, Z., Wang, W., Gao, J., Changgeng, F. U., & Liu, P. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1996288
Lin, J., & Bratkowski, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.21.755545
Newer Diabetes Medications in Older Adults with or At Risk for Cardiovascular Disease
Bovee, L. B., & Thirumalai, A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00469-y
Lee, Y. H., & Gyu, S. G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71525
Metadata
- Authors
- Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., PIONEER 2 Investigators, Cruz, P., Loredo, L. D., Luquez, C., Moisello, M., Augusto, G. A., Castro, M., Canani, L., Akrap, B., Bulum, T., Rahelic, D., Sunic-Grcic, I., Tusek, S., Avramidis, I., Benroubi, M., Didangelos, T., Karousos, G., Pagkalos, E., Sampanis, C., Somali, M., Domboróczki, Z., Faludi, P., Gaál, Z., Kis-Gombos, P., Kocsis, G., Marton, Z., Sudár, Z., Buscemi, S., Di Carlo, A., Dotta, F., Gambineri, A., Lauro, D., Maranghi, M., Arciszewska, M., Gumprecht, J., Matuszewska, K., Skokowska, E., Stasinska, T., Feofanova, S., Filippova, E., Galstyan, G., Gaysina, L., Kunitsyna, M., Suplotova, L., Antic, S., Djukic, A., Mitrovic, M., Pesic, M., Stokic, E., Jodar, E., Martínez, E., Raya, P. M., Montanya, E., Portillo, C. M., Vera, M. P., Fernández, M. R., San Jose, P., Riera, M. T., Boonyavarakul, A., Deerochanawong, C., Sriwijitkamol, A., Ajani, D., Armas, E., Barbel-Johnson, K., Bartilucci, D., Bonabi, G., Busch, R., Butuk, D., Cannon, K., Chase, C., Chaykin, L., Cheekati, V., Davis, T., Delgado, B., Farris, N., Graves, M., Ha, C., Harper, L., Herring, S., Hewitt, M., Hsia, D., Jackson, R., Jardula, M., Joyce, M., Juarez, M., Kapoor, A., Karounos, D., Kayne, D., Lacour, A., Ledesma, G., Lingvay, I., Lipetz, R., Lomboy, J., Lynd, S., Morawski, E., Morin, R., Murphy, R., Overcash, J. S., Pullman, J., Rodbard, H. W., Rosenstock, J., Ruoff, G., Steenkamp, D., Toro, H., Trachtenbarg, D., Tulloch, B., Weisbrot, A., & Wright, A.
- Affiliations
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Novo Nordisk (Denmark) (DK)
- ORCID
- Lindberg, Søren Østergaard
- Augusto, Gustavo Akerman
- Bulum, Tomislav
- Avramidis, Iakovos
- Didangelos, Triantafyllos
- Buscemi, Silvio
- Dotta, Francesco
- Gambineri, Alessandra
- Lauro, Davide
- Maranghi, Marianna
- Galstyan, Gagik
- Boonyavarakul, Apussanee
- Sriwijitkamol, Apiradee
- Busch, Robert
- Herring, Sharon
- Hsia, Daniel
- Overcash, J. Scott
- Steenkamp, Devin
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-10-07
- Volume
- 42
- Issue
- 12
- Pages
- 2272-2281
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2974621372
- Cited by
- 463
- References
- 37
- Citations by year
- 2026: 53 · 2025: 85 · 2024: 78 · 2023: 55 · 2022: 64 · 2021: 59 · 2020: 60 · 2019: 8
- FWCI
- 38.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Use Siena air (University of Siena) (submittedVersion)
- Lume (Universidade Federal do Rio Grande do Sul) (submittedVersion, cc-by-nc-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- oral semaglutide, empagliflozin, type 2 diabetes, metformin failure, GLP-1 receptor agonists, SGLT2 inhibitors, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, drug safety, treatment policy estimand
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.